Joana Carvalho, PhD, managing science editor —

A multidisciplinary approach is needed to evaluate patients suspected of having atypical hemolytic uremic syndrome (aHUS) and to select the best course of treatment in each instance, a case report says. The report, “A Multimodality Approach to Assessing Factor I Genetic Variants in Atypical Hemolytic Uremic Syndrome,” was…

The U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for Alexion‘s Ultomiris (ravulizumab-cwvz) for the treatment of patients with atypical hemolytic uremic syndrome (aHUS). aHUS is caused by the progressive destruction of red…

In some patients, atypical hemolytic uremic syndrome (aHUS) may be associated with heart disease, a case report study highlights. The case report study, “Atypical Hemolytic Uremic Syndrome Presenting as Acute Heart Failure — A Rare Presentation: Diagnosis Supported by Skin Biopsy,” was published in the Journal…

Rapid drug desensitization may allow patients with atypical hemolytic uremic syndrome (aHUS) to continue treatment with Soliris (eculizumab), following a medicine-induced allergic reaction, a case report says. The study, “Eculizumab hypersensitivity and desensitization in a toddler with atypical hemolytic uremic syndrome,” was published in The…

Hypertensive emergency and the presence of rare complement mutations are essential to estimate the prognosis of kidney disease in patients with atypical hemolytic uremic syndrome (aHUS). The study, “Impact Of Hypertensive Emergency And Complement Rare Variants On Presentation And Outcome Of Atypical Hemolytic Uremic Syndrome,” was published in…

Scientists have created a new mouse model for atypical hemolytic uremic syndrome (aHUS) that fully mirrors the clinical symptoms of the disease seen in human patients. The animals, which harbor a genetic mutation in the C3 protein, may be used in the future to test new therapeutic agents…

Laboratory tests to evaluate the long-term treatment effects of Soliris (eculizumab) on complement inhibition — stopping an overly aggressive immune response — in patients with atypical hemolytic uremic syndrome (aHUS) are useful, a case report shows. The case report study, “Clinical and Complement Long-Term Follow-Up of a Pediatric…